Complications After Prostate Biopsy: Data From SEER-Medicare
- 30 November 2011
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 186 (5), 1830-1834
- https://doi.org/10.1016/j.juro.2011.06.057
Abstract
More than 1 million prostate biopsies are performed annually among Medicare beneficiaries. We determined the risk of serious complications requiring hospitalization. We hypothesized that with emerging multidrug resistant organisms there may be an increasing risk of infectious complications. In a 5% random sample of Medicare participants in SEER (Surveillance, Epidemiology and End Results) regions from 1991 to 2007 we compared 30-day hospitalization rates and ICD-9 primary diagnosis codes for admissions between 17,472 men who underwent prostate biopsy and a random sample of 134,977 controls. Multivariate logistic and Poisson regression were used to examine the risk and predictors of serious infectious and noninfectious complications with time. The 30-day hospitalization rate was 6.9% within 30 days of prostate biopsy, which was substantially higher than the 2.7% in the control population. After adjusting for age, race, SEER region, year and comorbidities prostate biopsy was associated with a 2.65-fold (95% CI 2.47-2.84) increased risk of hospitalization within 30 days compared to the control population (p <0.0001). The risk of infectious complications requiring hospitalization after biopsy was significantly greater in more recent years (p(trend) = 0.001). Among men undergoing biopsy, later year, nonwhite race and higher comorbidity scores were significantly associated with an increased risk of infectious complications. The risk of hospitalization within 30 days of prostate biopsy was significantly higher than in a control population. Infectious complications after prostate biopsy have increased in recent years while the rate of serious noninfectious complications is relatively stable. Careful patient selection for prostate biopsy is essential to minimize the potential harms.Keywords
This publication has 20 references indexed in Scilit:
- Costs Attributable to Healthcare-Acquired Infection in Hospitalized Adults and a Comparison of Economic MethodsMedical Care, 2010
- Human Health Consequences of Use of Antimicrobial Agents in AquacultureClinical Infectious Diseases, 2009
- Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007Journal of Antimicrobial Chemotherapy, 2009
- Mortality Results from a Randomized Prostate-Cancer Screening TrialThe New England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyThe New England Journal of Medicine, 2009
- Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian regionClinical Microbiology & Infection, 2008
- Best Practice Policy Statement on Urologic Surgery Antimicrobial ProphylaxisJournal of Urology, 2008
- RISKS AND COMPLICATIONS OF TRANSRECTAL ULTRASOUND GUIDED PROSTATE NEEDLE BIOPSYJournal of Urology, 1998
- Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectivesJournal of Clinical Epidemiology, 1993
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987